This study is evaluating a new oral drug (called S095035) in adults with advanced or metastatic solid cancers with homozygous deletion of MTAPA Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP

Exclusion

• Inability to take an orally administered drug, or medical disorder or prior surgical resection that may affect the absorption of the study drug.
• Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's Medical monitor and investigator agree and document that it should not be exclusionary.
• Known prior severe hypersensitivity to any component of the study drug formulation.
• Major surgery within 4 weeks prior to the first IMP administration or participants who have not recovered from side effects of the surgery.
• Have a known history of Gilbert's syndrome.
• Participants with a known clinically significant cardiovascular disease or condition.
• Participants with thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to first IMP administration.
• Active brain metastases.
• Current active liver or biliary disease.
• Participants who have received systemic anticancer treatment or radiotherapy less than 2 weeks before the first dose of S095035. Participants who have not recovered from toxicity of previous anticancer therapy.